Cutaneous T-cell lymphoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:26:37 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cutaneous T-cell lymphoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of brentuximab vedotin for maintenance therapy in patients with cutaneous T-cell lymphoma after stem cell transplant https://clinicaltrials.eu/trial/study-of-brentuximab-vedotin-for-maintenance-therapy-in-patients-with-cutaneous-t-cell-lymphoma-after-stem-cell-transplant/ Wed, 29 Apr 2026 15:06:51 +0000 https://clinicaltrials.eu/trial/study-of-brentuximab-vedotin-for-maintenance-therapy-in-patients-with-cutaneous-t-cell-lymphoma-after-stem-cell-transplant/ This clinical trial focuses on patients with Cutaneous T-cell Lymphomas (CTCL), specifically Mycosis Fungoides, which is a rare type of skin lymphoma. The study evaluates the effectiveness of Brentuximab vedotin (also known as ADCETRIS) compared to placebo in patients who have recently undergone allogeneic hematopoietic stem cell transplantation (a procedure where a patient receives blood-forming stem cells from a donor).

The purpose of the study is to determine if Brentuximab vedotin can help prevent the lymphoma from returning or progressing after transplantation. The medication or placebo will be given through intravenous infusion, which means it will be administered directly into a vein. The treatment will continue for approximately 45 weeks.

During the study, patients will receive either Brentuximab vedotin or placebo as a maintenance treatment. The medication is provided as a solution for infusion that is prepared from a powder concentrate. Patients will be monitored for two years to assess how well the treatment works in preventing the disease from returning or getting worse.

]]> Study on the Safety and Effects of Tolinapant in Patients with Advanced Solid Tumors and Lymphomas https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-tolinapant-in-patients-with-advanced-solid-tumors-and-lymphomas/ Wed, 29 Apr 2026 14:59:44 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-tolinapant-in-patients-with-advanced-solid-tumors-and-lymphomas/ This clinical trial is focused on studying the effects of a medication called Tolinapant, also known by its code name ASTX660. The study is aimed at people with advanced forms of cancer, specifically solid tumors and lymphomas. These are types of cancers that have either spread to other parts of the body or cannot be removed through surgery. The specific types of cancer being studied include head and neck cancer, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, and cervical cancer, among others.

The purpose of the study is to evaluate the safety and effectiveness of Tolinapant in treating these advanced cancers. Participants in the study will receive the medication in the form of a capsule taken by mouth. The study will be conducted in phases, with the first phase already completed. The second phase will focus on assessing how well the medication works in reducing the size of tumors or slowing their growth. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of Tolinapant.

Throughout the study, participants will be monitored for any side effects and changes in their condition. The study aims to determine the best dose of Tolinapant and to gather information on how the body processes the medication. This information will help researchers understand the potential benefits and risks of using Tolinapant as a treatment for advanced cancers. The study is expected to continue until the end of 2025.

]]> Study of Mogamulizumab and Total Skin Electron Beam Therapy for Patients with Stage IB-IIB Cutaneous T-Cell Lymphoma https://clinicaltrials.eu/trial/study-of-mogamulizumab-and-total-skin-electron-beam-therapy-for-patients-with-stage-ib-iib-cutaneous-t-cell-lymphoma/ Wed, 29 Apr 2026 14:29:49 +0000 https://clinicaltrials.eu/trial/study-of-mogamulizumab-and-total-skin-electron-beam-therapy-for-patients-with-stage-ib-iib-cutaneous-t-cell-lymphoma/ This clinical trial is focused on studying a type of cancer called cutaneous T-cell lymphoma, which affects a kind of white blood cell and primarily involves the skin. The study specifically looks at two subtypes of this cancer: Mycosis Fungoides and Sézary Syndrome. The treatment being tested in this trial is a medication called mogamulizumab, also known by its code names KW-0761 and AMG 761. This medication is being used in combination with a treatment method called Total Skin Electron Beam therapy (TSEB), which involves using a special type of radiation to treat the skin.

The purpose of the study is to evaluate how well this combination treatment works in patients with stage IB to IIB cutaneous T-cell lymphoma. Participants in the study will receive the treatment and be monitored over a period of time to see how their cancer responds. The study will look at various outcomes, including how long patients live without their cancer getting worse, the overall safety of the treatments, and the response rate, which measures how many patients experience a reduction in their cancer.

Throughout the study, researchers will also assess other factors such as the overall survival of patients, the time it takes for the cancer to progress, and the duration of any positive response to the treatment. Additionally, the study will explore the impact of the treatment on patients’ quality of life. The trial is designed to gather important information that could help improve treatment options for people with this type of cancer in the future.

]]> Study of Lacutamab Alone or with Chemotherapy for Patients with Advanced T-Cell Lymphoma https://clinicaltrials.eu/trial/study-of-lacutamab-alone-or-with-chemotherapy-for-patients-with-advanced-t-cell-lymphoma/ Wed, 29 Apr 2026 14:29:49 +0000 https://clinicaltrials.eu/trial/study-of-lacutamab-alone-or-with-chemotherapy-for-patients-with-advanced-t-cell-lymphoma/ This clinical trial is focused on studying a type of cancer called T-cell lymphoma, which includes specific subtypes such as Cutaneous T-cell lymphoma and Mycosis fungoides. These are advanced forms of cancer that affect the skin and other parts of the body. The treatment being tested in this study is a medication called Lacutamab, also known by its code name IPH4102. Lacutamab is a type of protein treatment known as a monoclonal antibody, which is designed to target and attack cancer cells. The study will explore the effects of Lacutamab when used alone or in combination with chemotherapy.

The purpose of this study is to evaluate how well patients respond to the treatment. Participants will receive Lacutamab through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the participants over a period to see how their cancer responds to the treatment. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of Lacutamab. The study will also assess the safety of the treatment and any side effects that may occur.

Throughout the study, researchers will collect information on how the treatment affects the participants’ quality of life and overall health. This includes monitoring any changes in symptoms and conducting regular health checks. The study aims to provide valuable insights into the effectiveness of Lacutamab for treating advanced T-cell lymphoma and to determine if it can be a beneficial treatment option for patients with this type of cancer.

]]> Study on Tofacitinib for Patients with Mycosis Fungoides https://clinicaltrials.eu/trial/study-on-tofacitinib-for-patients-with-mycosis-fungoides/ Wed, 29 Apr 2026 14:25:16 +0000 https://clinicaltrials.eu/trial/study-on-tofacitinib-for-patients-with-mycosis-fungoides/ This clinical trial is focused on studying a type of cancer called Mycosis Fungoides, which is a form of skin lymphoma. The study is testing a medication known as Xeljanz, which contains the active ingredient tofacitinib. Tofacitinib is a chemical substance that works by inhibiting certain proteins in the body, specifically JAK1 and JAK3, which are involved in the immune response. The purpose of the study is to see if treatment with Xeljanz can decrease the activity of the disease.

Participants in the study will take Xeljanz in the form of film-coated tablets, which are taken orally. The study will observe how the disease responds to the treatment over a period of time, looking for changes such as complete response, partial response, stable disease, or progressive disease. The overall response rate to the treatment will also be evaluated. The study is open-label, meaning that both the researchers and participants know what treatment is being administered.

This trial is a pilot study, which means it is an initial, smaller-scale study designed to gather preliminary data. It aims to explore the effects of Xeljanz on the tumor microenvironment and skin barrier deficiency in patients with Mycosis Fungoides. The study will help determine if further research is warranted and provide insights into the potential benefits of using Xeljanz for this condition.

]]> Study of Linperlisib for Patients with Relapsed or Refractory Peripheral T/NK Cell or Cutaneous T Cell Lymphoma https://clinicaltrials.eu/trial/study-of-linperlisib-for-patients-with-relapsed-or-refractory-peripheral-t-nk-cell-or-cutaneous-t-cell-lymphoma/ Wed, 29 Apr 2026 14:25:04 +0000 https://clinicaltrials.eu/trial/study-of-linperlisib-for-patients-with-relapsed-or-refractory-peripheral-t-nk-cell-or-cutaneous-t-cell-lymphoma/ This clinical trial is focused on studying the effectiveness and safety of a medication called Linperlisib (also known by its code name YY-20394) in treating certain types of lymphoma. Lymphoma is a type of cancer that affects the lymphatic system, which is part of the body’s immune system. The specific types of lymphoma being studied in this trial are Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma. These are conditions where the cancerous cells are either in the lymph nodes or the skin. The trial is designed for patients whose lymphoma has returned after treatment or has not responded to previous treatments.

The purpose of this study is to evaluate how well Linperlisib works in treating these lymphomas. Participants in the study will take Linperlisib in the form of a tablet. The study will monitor the participants over a period of time to see how their lymphoma responds to the treatment. This includes checking if the cancer shrinks or disappears and observing any side effects that may occur. The study will also look at how long the response lasts and how the treatment affects the participants’ overall health and survival.

Participants will be closely monitored by a team of healthcare professionals throughout the study. This includes regular check-ups and tests to assess the progress of the treatment. The study aims to provide valuable information on the potential benefits and risks of using Linperlisib for treating these specific types of lymphoma. The results of this study could help improve treatment options for patients with these challenging conditions in the future.

]]>